Philogen S.p.A., a Siena, Italy-based clinical-stage biotechnology company focused on antibody-based therapeutics, raised €62m in financing.
Current and new private investors participated.
The company intends to use the funds to progress its wholly-owned pipeline products through clinical development and to expand its GMP facilities, enabling large scale production of antibody products.
Led by Dr. Duccio Neri, Chief Executive Officer, Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products. Its strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically target stromal antigens.
The company currently has two products in Phase III development for oncological indications. Daromun is being investigated for the treatment of fully resectable Stage III B / C melanoma while Fibromun is being studied in metastatic soft tissue sarcoma. The pipeline is complemented by other products that are in Phase I or Phase II clinical trials.
In addition to its validating partnerships with big pharma, Philogen has an IP position with more than 40 international patent families and is a fully integrated company from discovery to GMP manufacturing and clinical trial execution.
The company, which has research activities at its subsidiary company Philochem in Zürich, Switzerland, also announced the appointment of three new board members:
– Dr. Guido Guidi, who previously Head of Oncology Europe at Novartis,
– Dr. Roberto Marsella, who previously Director of Investments of Fondo Strategico Italiano / CDP Equity, now with Generali, and
– Dr. Roberto Ferraresi, who previously partner of PAI partners and currently CEO of The Equity Club.